Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshiyuki Someya

Showing results (11-20 of 269) with videos related to

Pageof 27
Sort By:
Psychiatry and Clinical Neurosciences|February 23, 2012
Delirium associated with duloxetine in a depressed patient with Alzheimer's dementiaYutaro Suzuki, Mami Saito, Toshiyuki Someya
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 6, 2005
Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patientsYutaro Suzuki, Kazushi Sawamura, Toshiyuki Someya
Psychiatry and Clinical Neurosciences|February 27, 2013
Association of the BDNF C270T polymorphism with schizophrenia: updated meta-analysisYuichiro Watanabe, Ayako Nunokawa, Toshiyuki Someya
Psychiatric Services (Washington, D.C.)|July 3, 2007
Suicide in JapanRyo Abe, Toshiki Shioiri, Toshiyuki Someya
Psychiatry and Clinical Neurosciences|September 5, 2014
QT prolongation associated with memantine in Alzheimer's diseaseHiromi Takehara, Yutaro Suzuki, Toshiyuki Someya
European Journal of Clinical Pharmacology|September 7, 2004
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetineKazushi Sawamura, Yutaro Suzuki, Toshiyuki Someya
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 26, 2015
DRD2 Ser311Cys polymorphism and risk of schizophreniaYuichiro Watanabe, Masako Shibuya, Toshiyuki Someya
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|August 17, 2006
[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia]Yutaro Suzuki, Hitoshi Sawamura, Toshiyuki Someya
Current Atherosclerosis Reports|December 11, 2012
Lipid effects of psychiatric medicationsJunzo Watanabe, Yutaro Suzuki, Toshiyuki Someya
Journal of Epidemiology|January 7, 2014
Psychological recovery 5 years after the 2004 Niigata-Chuetsu earthquake in Yamakoshi, JapanKazutoshi Nakamura, Kaori Kitamura, Toshiyuki Someya
Pageof 27

Showing results (11-20 of 269) with videos related to

Sort By:
Pageof 27
Psychiatry and Clinical Neurosciences|February 23, 2012
Delirium associated with duloxetine in a depressed patient with Alzheimer's dementiaYutaro Suzuki, Mami Saito, Toshiyuki Someya
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 6, 2005
Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patientsYutaro Suzuki, Kazushi Sawamura, Toshiyuki Someya
Psychiatry and Clinical Neurosciences|February 27, 2013
Association of the BDNF C270T polymorphism with schizophrenia: updated meta-analysisYuichiro Watanabe, Ayako Nunokawa, Toshiyuki Someya
Psychiatric Services (Washington, D.C.)|July 3, 2007
Suicide in JapanRyo Abe, Toshiki Shioiri, Toshiyuki Someya
Psychiatry and Clinical Neurosciences|September 5, 2014
QT prolongation associated with memantine in Alzheimer's diseaseHiromi Takehara, Yutaro Suzuki, Toshiyuki Someya
European Journal of Clinical Pharmacology|September 7, 2004
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetineKazushi Sawamura, Yutaro Suzuki, Toshiyuki Someya
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 26, 2015
DRD2 Ser311Cys polymorphism and risk of schizophreniaYuichiro Watanabe, Masako Shibuya, Toshiyuki Someya
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|August 17, 2006
[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia]Yutaro Suzuki, Hitoshi Sawamura, Toshiyuki Someya
Current Atherosclerosis Reports|December 11, 2012
Lipid effects of psychiatric medicationsJunzo Watanabe, Yutaro Suzuki, Toshiyuki Someya
Journal of Epidemiology|January 7, 2014
Psychological recovery 5 years after the 2004 Niigata-Chuetsu earthquake in Yamakoshi, JapanKazutoshi Nakamura, Kaori Kitamura, Toshiyuki Someya
Pageof 27